Molecular Hydrogen and COVID-19: What the Research Actually Found
When the COVID-19 pandemic began, I followed the molecular hydrogen research very closely. By 2022, I had accumulated enough material to build one of the most detailed H2Minutes reviews we had ever produced: preclinical studies, human studies, reviews, hypotheses, government guidance, clinical observations, and supporting respiratory research.
The reason H₂ became scientifically interesting was not complicated. Severe COVID-19 could involve oxidative stress, excessive inflammatory signaling, alveolar injury, impaired gas exchange, hypoxemia, mucus accumulation, increased work of breathing, and multi-organ damage. Molecular hydrogen had already been studied for many of those same biological problems.
Since then, additional COVID-19 studies have been published—including randomized and controlled clinical work, post-COVID rehabilitation research, and a 2024 phase I study using lower-concentration pure molecular hydrogen.
So this updated article is no longer just a list of reasons H₂ might help. It is a look back at what researchers proposed, what was actually tested in people, what the clinical studies found, and what I think the evidence tells us now.
Key Takeaways
- China’s National Health Commission historically added 66.6% H₂ / 33.3% O₂ mixed-gas inhalation to its COVID-19 treatment guidance when conditions permitted.
- Human COVID-19 studies reported favorable signals involving dyspnea, coughing, chest distress, chest pain, resting oxygen saturation, disease severity, hospitalization outcomes, inflammation, and recovery.
- A 2022 post-COVID study using pure H₂ inhalation improved six-minute walking distance and respiratory-function measures, which is important because the COVID literature is not limited to oxyhydrogen systems.
- A 2024 phase I study reported good tolerance of 3.6% H₂ in nitrogen in hospitalized patients with moderate COVID-19, adding evidence that lower-concentration pure-H₂ delivery can also be studied clinically.
- At H2HUBB, we do not interpret the COVID research as proof that oxyhydrogen is inherently more therapeutic than pure H₂ or H₂ mixed with air. Molecular hydrogen is the common therapeutic gas across these delivery methods.
- In 2026, I think the strongest way to describe this evidence is that molecular hydrogen has credible adjunctive therapeutic potential for COVID-related respiratory and inflammatory stress, while optimal concentration, timing, delivery method, and patient selection still need stronger comparative trials.
China’s National Health Commission Recommended H₂/O₂ Inhalation During the Pandemic
This part of the hydrogen-COVID story is important because it is often repeated inaccurately.
In March 2020, China’s National Health Commission released the seventh edition of its COVID-19 diagnosis and treatment guidance. In the general-treatment section, the guidance added that hydrogen-oxygen mixed inhalation gas at approximately 66.6% H₂ and 33.3% O₂ could be used when conditions permitted.
That recommendation was later carried into subsequent Chinese guidance. It was based on early clinical use of hydrogen-oxygen generators and the work surrounding Dr. Zhong Nanshan’s respiratory team.
I think that history matters because hydrogen was not simply being discussed on wellness blogs. It entered a national clinical guidance document during a respiratory pandemic.
At the same time, I would not turn that historical recommendation into a claim that one specific machine type was proven superior. The published studies tested particular hydrogen-delivery systems. They did not establish that every oxyhydrogen machine is better than every pure-H₂ or H₂-air system.
Follow the COVID-19 Evidence Into the H2HUBB Research Library
The H2HUBB Research Library contains more than 1,600 molecular hydrogen studies and scientific records. COVID-19 is especially useful for understanding H₂ because the literature spans mechanisms, pulmonary models, acute human disease, rehabilitation, hydrogen-rich water, oxyhydrogen, and pure-H₂ inhalation.
We also have a dedicated H2HUBB record for the 2024 moderate-COVID hydrogen inhalation study, so readers can move from this article directly into the study-level evidence.
Explore the H2HUBB Research Library →Why Molecular Hydrogen Became So Interesting for COVID-19
COVID-19 is caused by SARS-CoV-2, but the severity of the disease is not determined by viral replication alone. In more serious cases, the host response becomes part of the problem.
Researchers documented increases in reactive oxygen species, inflammatory cytokines, alveolar-cell injury, apoptosis, endothelial dysfunction, impaired oxygen exchange, hypoxemia, and—in the most serious cases—multi-organ dysfunction.
That created an unusually strong mechanistic overlap with the existing molecular hydrogen literature.
When I made H2Minutes Episode 59, I organized this biology into 10 practical ways hydrogen could potentially benefit COVID-19. I still think that framework is useful, but today we can strengthen it with additional human evidence that was published after the original video research.
What the Human COVID-19 Studies Actually Found
H₂/O₂ Improved Several Respiratory Outcomes Compared With Control Care
One of the most important early studies was a multicenter, open-label clinical trial conducted in China using an electrolyzed hydrogen-oxygen mixture of approximately 66% H₂ and 33% O₂.
The researchers evaluated disease severity, dyspnea, cough, chest distress, chest pain, and resting oxygen saturation. The H₂/O₂ group showed faster improvement in several outcomes, with differences becoming apparent as early as days two and three.
The study reported that 70.5% of patients in the H₂/O₂ group showed improvement in disease severity compared with 31.8% in the control group at the relevant assessment, while dyspnea improvement was also greater in the hydrogen-oxygen group.
This was not a blinded placebo-controlled trial, so I would not treat it as the final word. But it provided actual clinical evidence that the respiratory improvements being proposed from H₂ biology could be observed in hospitalized patients.
Pure H₂ Inhalation Improved Physical and Respiratory Recovery
The post-COVID study is especially important to me because it helps answer a question I have been asked for years: Does the therapeutic signal depend on using oxyhydrogen?
In this study, participants recovering from COVID-19 used molecular hydrogen inhalation at home for two one-hour sessions per day over 14 days. The hydrogen group improved six-minute walking distance by approximately 64 meters, compared with about 9 meters in the placebo group.
Researchers also reported improvements in respiratory-function measures, and the change in six-minute walking distance exceeded the commonly cited threshold for a clinically meaningful improvement in chronic respiratory disease.
This matters because it demonstrates favorable human outcomes using a pure-H₂ approach, not only the 66/33 oxyhydrogen mixture used in the Chinese acute-COVID studies.
1Oxidative Stress and Redox Imbalance
Oxidative stress was one of the strongest biological reasons molecular hydrogen was proposed for COVID-19.
SARS-CoV-2 infection can increase reactive oxygen species through viral replication, immune-cell activation, mitochondrial stress, inflammatory signaling, and tissue injury. When those oxidants overwhelm normal cellular defenses, the result can be lipid damage, protein oxidation, mitochondrial dysfunction, apoptosis, and further inflammatory activation.
Molecular hydrogen has repeatedly been shown to regulate this redox environment.
Older hydrogen literature described H₂ as a selective antioxidant because it reduced highly cytotoxic reactive species while preserving molecules involved in normal signaling. More recent research has broadened that model: H₂ also appears to influence Nrf2/Keap1 signaling, endogenous antioxidant defenses, mitochondrial function, inflammatory transcription factors, and redox-sensitive gene expression.
That distinction matters. The objective is not to eliminate every reactive oxygen species. ROS are part of normal immune and cellular signaling. The more interesting role for H₂ is helping regulate excessive oxidative stress while preserving redox homeostasis.
COVID-focused reviews specifically proposed that H₂ could reduce ROS production in alveolar epithelial cells, help preserve the alveolar epithelial barrier, improve gas-exchange conditions, and reduce oxidative cell injury.
2Excessive Inflammation and Cytokine Signaling
The second major area is inflammation.
Severe COVID-19 became closely associated with dysregulated inflammatory signaling and elevated cytokines. Terms such as “cytokine storm” were used heavily early in the pandemic, but the central idea is straightforward: in some patients, inflammatory signaling becomes excessive enough that the host response contributes to lung injury and systemic complications.
This is another place where molecular hydrogen had a strong existing research base.
Hydrogen studies have reported effects on TNF-α, IL-1β, IL-6, IL-10, HMGB1, NF-κB, NLRP3 inflammasome activity, neutrophil infiltration, macrophage activity, and other immune pathways.
In respiratory research outside COVID-19, hydrogen inhalation had already reduced airway inflammatory markers in asthma and COPD models and human studies. That gave researchers a reason to propose H₂ for the excessive pulmonary inflammation seen with SARS-CoV-2.
From our position at H2HUBB, I think this is better described as immune and inflammatory regulation than simply calling H₂ an “anti-inflammatory.” The goal is not to shut the immune system down. It is to reduce excessive inflammatory signaling and collateral tissue damage while maintaining normal host-defense function.
Explore the broader H₂ evidence on inflammatory signaling, cytokines, macrophages, oxidative stress, and immune regulation.
3Hypoxia, Reoxygenation, and Lung Injury
Hypoxia means inadequate oxygen at the tissue level, while hypoxemia refers to low oxygen in the blood. Both became major clinical concerns during severe COVID-19.
The lung injury behind this can involve alveolar damage, inflammation, edema, mucus, vascular changes, and impaired gas exchange. In critical illness, oxygen therapy and mechanical ventilation can be necessary and lifesaving, but severe lung disease also creates a complicated environment where oxidative stress, pressure-related injury, and reoxygenation injury may contribute additional cellular stress.
Hydrogen had already been studied in hypoxia/reoxygenation and ventilator-induced lung-injury models. Research reported reductions in inflammatory responses, oxidative injury, and apoptosis.
This is important context: the proposed role of H₂ was never simply to “add oxygen.” It was to potentially help protect pulmonary cells from the biological injury that accompanies severe oxidative and inflammatory stress.
A separate body of inhalation-safety research also shows that low-concentration molecular hydrogen does not bind hemoglobin and, under studied steady-state conditions, has not meaningfully disrupted arterial oxygen saturation in healthy participants.
4Alveolar Cells and Pulmonary Surfactant
Pulmonary surfactant reduces surface tension inside the alveoli, helps prevent alveolar collapse, and supports efficient gas exchange. It is largely produced by type II alveolar epithelial cells.
SARS-CoV-2 can injure these cells and disrupt normal alveolar function. That is one reason researchers became interested in whether H₂ could protect type II alveolar epithelial cells and related surfactant pathways.
Preclinical hydrogen studies have reported protection of type II alveolar epithelial cells during acute lung injury, reductions in excessive autophagy and apoptosis, and changes in surfactant-related genes.
This is not one of the better-developed human COVID outcomes, so I would keep it in the mechanistic category. But it adds another biologically plausible route through which H₂ could help preserve pulmonary function during severe respiratory stress.
5Airway Resistance and the Physical Properties of H₂/O₂
This section is different because part of the effect may be physical rather than biochemical.
Hydrogen has an extremely low density. In the Chinese H₂/O₂ trials, researchers proposed that the lower-density gas mixture reduced inspiratory effort as it moved through narrowed or obstructed airways.
That means the 66/33 hydrogen-oxygen mixture potentially offered two kinds of benefit at the same time:
- a physical gas-flow effect that may reduce airway resistance and the work of breathing; and
- a molecular H₂ effect involving oxidative stress, inflammation, and cellular protection.
This distinction is important when comparing device types. It gives us a reasonable explanation for why that particular H₂/O₂ mixture performed well in patients with respiratory compromise without proving that oxyhydrogen is inherently the most therapeutic form of hydrogen for every disease model.
6Dyspnea and Respiratory Comfort
Dyspnea—shortness of breath—was one of the outcomes where the early human H₂/O₂ data was most interesting.
The multicenter study reported faster improvement in dyspnea, chest distress, cough, and chest pain with H₂/O₂ than with the control approach. Earlier pilot experience also described patients feeling that breathing became easier after the gas was introduced.
Supporting respiratory research outside COVID-19 also matters. A multicenter randomized trial in COPD found that hydrogen-oxygen inhalation improved breathlessness, cough, and sputum scores compared with oxygen therapy.
So when I look at the dyspnea data, I do not think we have to explain it with one mechanism. Lower gas density, reduced airway resistance, inflammatory regulation, mucus effects, and pulmonary cellular protection could all contribute.
7Mucus Accumulation, Sputum, and Small-Airway Function
One of the findings emphasized by Dr. Zhong’s team was the presence of thick, viscous secretions in the lungs of some severe COVID-19 patients.
Mucus is part of normal host defense, but excessive secretion can obstruct smaller airways, increase resistance, worsen ventilation, and make oxygen delivery less efficient.
Hydrogen research in respiratory models has reported reductions in Muc5ac expression, goblet-cell hyperplasia, airway inflammation, and mucus secretion. COVID-focused reviews therefore proposed that hydrogen could help with sputum dilution and airway resistance.
This is another area where I would separate direct clinical evidence from supporting biology. We have respiratory and animal evidence suggesting H₂ can affect mucus-related pathways, plus clinical COVID studies showing improvement in dyspnea and respiratory symptoms. The exact contribution of mucus reduction in COVID patients still needs more direct measurement.
8Multi-Organ Protection
COVID-19 is primarily known as a respiratory infection, but severe disease can affect the cardiovascular system, kidneys, nervous system, vascular endothelium, and other organs.
This was one reason researchers looked at hydrogen as a potentially useful adjunctive molecule. H₂’s anti-apoptotic, redox-regulating, anti-inflammatory, and mitochondrial effects had already been demonstrated in models involving the heart, kidneys, brain, liver, and other tissues.
That broader organ-protection literature does not prove that hydrogen prevented multi-organ failure in COVID-19 patients. But it created a reasonable systems-level hypothesis: if one therapy can regulate several of the stress pathways activated across multiple organs, it may have value in a disease that is itself multi-systemic.
9Disease Severity and Clinical Recovery
This is where the COVID evidence becomes more clinically meaningful.
In the early multicenter H₂/O₂ study, the hydrogen-oxygen group showed significantly greater improvement in disease severity, dyspnea, cough, chest distress, chest pain, and resting oxygen saturation than the comparison group.
Later studies continued to build on that signal.
A 2023 propensity-score matched study of hospitalized patients with ordinary COVID-19 reported that H₂/O₂ therapy was associated with improved oxygen saturation and shorter hospitalization. Another 2023 multicenter randomized study evaluated H₂/O₂ during Omicron infection and reported favorable recovery outcomes.
These studies are still relatively small compared with the massive clinical programs behind established COVID therapeutics. But they move the hydrogen discussion beyond theory. There is now a set of human clinical studies pointing in a consistent direction across respiratory symptoms, oxygenation, recovery, and functional outcomes.
10Post-COVID Recovery, Exercise Tolerance, and Respiratory Function
When I made the original H2Minutes video, this was one of the most intriguing parts of the research because the pandemic had already created a large population of people who were no longer acutely ill but still did not feel normal.
Participants in the 2022 post-COVID study were generally functioning reasonably well but continued to experience symptoms such as fatigue, dyspnea, or muscle soreness.
After 14 days of H₂ inhalation, the hydrogen group improved six-minute walking distance by about 64 meters. Researchers also reported respiratory-function benefits and improved cardiorespiratory capacity.
The authors compared the magnitude of the walking improvement with a longer supervised exercise-rehabilitation program and proposed that hydrogen could be a time-efficient adjunct to established rehabilitation.
I think the important word there is adjunct. H₂ does not need to replace exercise rehabilitation to be useful. If it can improve tolerance, respiratory function, fatigue, or recovery enough to help someone participate more effectively in rehabilitation, that may be clinically meaningful.
Hydrogen-rich water has also been explored in COVID and post-COVID settings, including fatigue and inflammatory outcomes, giving us another route of administration worth investigating.
Does the COVID Research Prove Oxyhydrogen Is Better Than Pure H₂?
No Direct Human Comparison Has Established Oxyhydrogen Superiority
This is one of the most important clarifications I want to make because I have had consumers and companies tell me that the COVID studies prove Brown’s Gas or oxyhydrogen is more therapeutic than pure hydrogen.
I do not think the research supports that conclusion.
The major Chinese acute-COVID studies used an approximately 66% H₂ / 33% O₂ mixture. Those studies tell us that this mixture produced favorable clinical outcomes. They do not tell us that the same patients would have done worse with an appropriately dosed pure-H₂ or H₂-air system, because those delivery methods were not directly compared head-to-head in the same human trial.
We also have favorable COVID-related human evidence using pure molecular hydrogen. The 2022 post-COVID rehabilitation study used pure H₂ inhalation, and a 2024 phase I trial evaluated 3.6% H₂ mixed with nitrogen in hospitalized moderate-COVID patients.
For me, the common denominator across these systems is H₂.
The additional oxygen in an oxyhydrogen system can be useful when a patient needs supplemental oxygen, and the low density of the H₂/O₂ mixture may reduce airway resistance. But those are context-specific advantages. They are not the same thing as proving oxyhydrogen has a universally greater molecular-hydrogen therapeutic effect.
Could higher H₂ concentrations sometimes produce a greater biological dose and therefore a greater effect? Absolutely—that is plausible, and dose-dependent responses have been reported in other hydrogen models. But if we follow that logic, we still have to distinguish H₂ concentration from whether oxygen is mixed with it.
At H2HUBB, we evaluate pure H₂, H₂ mixed with air, and oxyhydrogen as different delivery technologies with different strengths, limitations, and safety considerations. We do not turn a study on one delivery method into a claim that every other method is inferior.
Our complete inhalation guide explains how the major device categories differ and how we estimate practical inhaled-H₂ concentration.
What Newer COVID-19 Hydrogen Research Added After the Original H2Minutes Video
The Clinical Evidence Did Not Stop in 2022
The article originally published on H2HUBB in 2023 was based heavily on the research available through the first years of the pandemic. Since then, more human data has been published.
2023: Randomized Omicron Study
A prospective multicenter randomized study enrolled 64 hospitalized patients during the Omicron period and compared hydrogen-oxygen inhalation with oxygen inhalation. The study was designed to evaluate whether the earlier respiratory benefits would also translate to Omicron-era disease.
View the 2023 randomized Omicron study →
2023: Propensity-Matched Ordinary COVID-19 Study
A separate multicenter study collected data from 180 hospitalized patients and used propensity-score matching to compare H₂/O₂ therapy with oxygen therapy. The authors reported improved oxygen saturation and shorter hospitalization in the hydrogen-oxygen group, while also acknowledging that the level of evidence remained limited and stronger trials were needed.
View the 2023 propensity-matched study →
2024: Lower-Concentration Pure H₂ in Moderate COVID-19
A phase I clinical trial evaluated a mixture of 3.6% H₂ and 96.4% N₂ in 12 hospitalized patients with moderate COVID-19. The authors reported excellent tolerance and no safety signal that prevented continued investigation. Because this was a small phase I study without the kind of large controlled design needed to prove efficacy, I view it primarily as an important safety and feasibility addition to the literature.
This is also strategically important for H2HUBB because it demonstrates that COVID-19 hydrogen research is not limited to a 66/33 oxyhydrogen model.
What I Think the COVID-19 Evidence Shows Today
When we first made the H2Minutes COVID video, the field was moving very fast. Much of the discussion was mechanistic, early clinical, or hypothetical.
Today, I think we can make a stronger statement while still staying proportional to the evidence.
Molecular hydrogen has a credible human evidence base supporting therapeutic potential in COVID-related respiratory stress and post-COVID recovery. We have studies using H₂/O₂ in acute disease, pure H₂ in post-COVID rehabilitation, hydrogen-rich water in COVID-related fatigue and inflammation, and lower-concentration H₂ inhalation in hospitalized moderate disease.
The findings are not all from the same protocol, which is both a strength and a limitation. It tells us the therapeutic signal may extend across different administration methods, but it also means we still need better studies defining optimal dose, timing, concentration, duration, and patient population.
I also think the COVID literature reinforces something we teach throughout H2HUBB: the machine label is not the dose. “Oxyhydrogen,” “pure H₂,” or “mixed-air H₂” describes how a device produces or delivers gas. What ultimately matters is how much molecular hydrogen reaches the user, how safely it is delivered, and whether the exposure is relevant to the research.
How I Would Position H₂ Today
COVID care has changed substantially since the early pandemic. In the United States, current clinical care includes antiviral treatment for eligible higher-risk patients, with timing of therapy being important.
So in 2026, I would describe molecular hydrogen as an adjunctive research therapy with promising respiratory, inflammatory, redox, and recovery data—not as a reason to delay testing, antiviral treatment, oxygen support, emergency evaluation, or other appropriate medical care.
That framing respects both sides of the evidence: the H₂ research is meaningful and deserves to be taken seriously, while COVID treatment decisions still need to reflect the patient’s actual disease severity, risk factors, oxygen status, and current medical guidance.
Molecular Hydrogen & COVID-19 FAQ
Was hydrogen actually used for COVID-19 patients?
Yes. Hydrogen-oxygen mixed gas was used clinically in China and was included in China’s national COVID-19 guidance when conditions permitted. Multiple human studies later evaluated H₂/O₂, pure H₂, and hydrogen-rich water in acute or post-COVID settings.
What concentration did China recommend?
The historical Chinese guidance referenced hydrogen-oxygen mixed gas at approximately 66.6% H₂ and 33.3% O₂.
Did hydrogen improve COVID-19 symptoms in human studies?
Several studies reported favorable outcomes. Depending on the study, researchers observed improvements in disease severity, dyspnea, cough, chest distress, chest pain, resting oxygen saturation, hospitalization outcomes, physical function, or respiratory recovery.
Does the research prove oxyhydrogen is better than pure H₂?
No direct human head-to-head study discussed here establishes that conclusion. Oxyhydrogen produced favorable results in acute COVID studies, while pure-H₂ inhalation also produced favorable human outcomes in post-COVID rehabilitation and has been evaluated in moderate COVID. At H2HUBB, we separate the therapeutic H₂ dose from the specific device category.
Why would molecular hydrogen affect inflammation?
H₂ research has demonstrated effects on redox signaling, NF-κB, Nrf2, NLRP3 inflammasome activity, inflammatory cytokines, macrophages, neutrophils, mitochondrial ROS, apoptosis, and other pathways involved in inflammatory tissue injury.
Was hydrogen studied for post-COVID symptoms?
Yes. A 2022 study reported that 14 days of H₂ inhalation improved six-minute walking distance and respiratory-function measures in acute post-COVID patients. Hydrogen-rich water has also been explored for fatigue, inflammation, oxygenation, and exercise tolerance.
Is hydrogen inhalation the only way H₂ was studied for COVID-19?
No. Most of the major acute respiratory studies used inhaled H₂, but hydrogen-rich water and hydrogen-producing tablets were also investigated in COVID-related research.
Where can I learn more about hydrogen inhalation dosing and device types?
Read our Hydrogen Inhalation Therapy: The Ultimate Guide for a detailed H2HUBB explanation of pure H₂, oxyhydrogen, H₂ mixed with air, measured gas output, estimated inhaled-H₂ concentration, safety, and practical dosing.
Where can I read the molecular hydrogen studies directly?
Use the H2HUBB Molecular Hydrogen Research Library to search source-linked human, animal, mechanistic, and review literature.